Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The study record adds a named contact entry (Myung-Ju Ahn) and new help/navigation links (How to Read a Study Record, Common Questions, How to Join a Study), and adjusts the Intervention/Treatment label and related status wording.
    Difference
    1%
    Check dated 2026-06-12T16:30:21.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.5, replacing the previous Revision: v3.5.4. This indicates a recent editorial/system update to the page rather than a modification to study content.
    Difference
    0.1%
    Check dated 2026-06-05T12:18:37.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The page's revision tag changed from v3.5.3 to v3.5.4, indicating a minor platform update. There is no evidence of changes to the study details or other content on the page.
    Difference
    0.1%
    Check dated 2026-05-15T03:14:37.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    A bibliographic citation was added referencing the 2012 NEJM article 'Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.' This background reference situates the trial within the broader PD-L1 inhibitor literature.
    Difference
    0.1%
    Check dated 2026-05-07T23:13:02.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    Revision updated from v3.5.2 to v3.5.3, signaling a new release of the page content. This update represents a metadata/version change rather than substantive changes to the study details.
    Difference
    0.1%
    Check dated 2026-04-30T17:33:09.000Z thumbnail image
  8. Check
    62 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 and removed an older NEJM trial citation from the page; no substantive study details, eligibility criteria, or outcomes were altered.
    Difference
    0.1%
    Check dated 2026-04-16T10:30:29.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.